Fingerprint
Dive into the research topics of 'Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically